Skip to main content
Shilpa Medicare Ltd. logo

Shilpa Medicare Ltd. — Investor Relations & Filings

Ticker · SHILPAMED ISIN · INE790G01031 LEI · 3358002PKUL8S2RNJO60 BSE.NS Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-11-13 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS SHILPAMED

About Shilpa Medicare Ltd.

https://vbshilpa.com/

Shilpa Medicare Ltd. is a research-led organization specializing in the development, manufacture, and commercialization of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the oncology segment, producing a wide range of high-potency anti-cancer drugs. Its capabilities extend to diverse therapeutic areas, including ophthalmology, dermatology, and biosimilars. Shilpa Medicare operates manufacturing facilities compliant with international regulatory standards such as the USFDA and EU-GMP. The organization emphasizes complex chemistry and advanced drug delivery systems, offering a portfolio that includes oral solids, injectables, and transdermal patches. Through its R&D infrastructure, the company provides contract research and manufacturing services to global partners, supporting the lifecycle of generic and innovative pharmaceutical products.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a formal stock‐exchange filing under SEBI Regulations 30 and 33, providing the Board’s approval and detailed Unaudited Standalone and Consolidated Financial Results for the quarter and half‐year ended September 30, 2025. It includes full income, expense, tax and earnings tables (actual financial statements) rather than just highlights or a brief announcement. This matches the definition of an Interim/Quarterly Report (IR) containing substantive financial data for a period shorter than a full fiscal year. H1 2025
2025-11-13 English
Outcome of Board Meeting
Regulatory Filings
2025-11-13 English
General Updates
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed corporate communication from Shilpa Medicare Limited addressed to stock exchanges, discussing the results of a postal ballot and enclosing newspaper advertisements of the results. It references compliance with SEBI (LODR) Regulations, 2015, specifically Regulation 30 and 44, which pertain to disclosure obligations and voting results. The content includes detailed financial and operational updates of various companies, but the primary focus is on the postal ballot results announcement. The document is about the announcement of voting results from a shareholder postal ballot, not the full report or detailed financial statements. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial but the core purpose is the announcement of voting results, not a full annual or interim report or other filings.
2025-11-11 English
Shareholders meeting
Regulatory Filings
2025-11-10 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a press release announcing positive Phase 3 clinical trial results for a pharmaceutical product (OERIS™) by Shilpa Medicare Limited. It includes detailed study design, endpoints, results, and next regulatory steps. The document is addressed to stock exchanges under SEBI (LODR) regulations, indicating it is a regulatory announcement. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an annual or interim report, nor a call transcript or governance document. The content is focused on clinical trial results and regulatory progress, typical of a press release or capital/financing update related to product development milestones. Given the nature and length (6198 characters), it is not a report publication announcement but a substantive announcement. The best fitting category is Capital/Financing Update (CAP), as it relates to significant company progress impacting valuation and investor information about product pipeline and regulatory pathway.
2025-11-10 English
General Updates
Environmental & Social Information Classification · 95% confidence The document is a formal announcement from Shilpa Medicare Limited to stock exchanges regarding an award received by its subsidiary for excellence in sustainability. It highlights the EcoVadis Gold Medal award, the company's ESG performance, and includes statements from the CEO emphasizing sustainability efforts. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The content focuses on environmental, social, and governance (ESG) achievements and sustainability recognition. The document length is short (3106 characters), and it is clearly an announcement rather than a detailed report. Therefore, the most appropriate classification is Environmental & Social Information (SR).
2025-11-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.